Year: 2026

Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference testing NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its initial clinical Cut-off Study supporting the Company’s FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. The clinical Cut-off Study evaluated codeine detection cut-off levels in 40 adults, with full data analysis completed as planned by...

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court for the Southern District of New York has largely ruled against defendants CIBC World Markets (“CIBC”) and RBC Dominion Securities (“RBC”) joint motion to dismiss Quantum Biopharma’s lawsuit alleging illegal market manipulation. The Quantum Biopharma lawsuit alleges that between January 1, 2020, and August 15, 2024, the Defendants and/or their customers used “spoofing” techniques to manipulate the share price of Quantum BioPharma shares. The Company alleges that these market manipulation schemes violated Section 10(b) and Rule 10b-5(a)...

New Platform Capabilities Designed to Increase Revenue Per Store and Further Integrate SurgePays into Core Merchant Operations BARTLETT, Tenn., April 02, 2026 (GLOBE NEWSWIRE) — SurgePays, Inc. (NASDAQ: SURG) (“SurgePays” or the “Company”), a wireless and fintech technology company connecting subprime and underserved consumers to essential mobile and financial services, today announced the launch of its stored value and loyalty platform, a fully customizable white label program available to merchants across its nationwide retail network. The stored value platform enables merchants, ranging from single location operators to large retail chains, to offer branded gift cards, store credits, and loyalty programs directly to their customers. SurgePays will manage the full lifecycle of the program, including balance tracking, transaction...

New regional partnership strengthens Nanox’s presence and service support across outpatient imaging settings in Colorado, Wyoming and the western parts of Kansas and Nebraska Agreement aligns with Nanox’s strategy to expand through regional distributors with strong commercial reach and service infrastructurePETACH TIKVA, Israel, April 2, 2026 (GLOBE NEWSWIRE) — Nano-X Imaging Ltd. (NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a new distribution agreement with Integrity Medical Service Inc., a Colorado based provider of imaging solutions serving hospitals, orthopedic practices, imaging centers, and outpatient providers. Under the terms of the agreement, Integrity Medical Service will lead sales, implementation and service support for...

New solution can reduce prescreen build times by up to 75% CHICAGO, April 02, 2026 (GLOBE NEWSWIRE) — With consumer credit originations expected to rise in 2026, lenders have a significant opportunity to drive growth through faster, more effective prescreen marketing campaigns. Yet many organizations struggle to execute these programs efficiently. A TransUnion-commissioned Forrester study found that 42% of financial services and insurance executives rely on basic segmentation, and nearly one-third lack meaningful personalization—even as consumers increasingly expect tailored experiences. To help lenders overcome these challenges, TransUnion has launched TruIQ Credit Strategy Studio. This self-service prescreen solution streamlines campaign development and activation, reducing prescreen build times by up to 75% and shrinking weeks-long...

Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) — Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage therapeutics company, today announced that it is expanding its drug development pipeline that encompassed six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (“NAFLD”), and gout, by focusing on a new core indication: cancer cachexia, a serious cancer-associated wasting syndrome marked by progressive weight loss, muscle depletion, weakness and declining physical function. Cancer cachexia is widely recognized as one of the most serious complications in oncology and is estimated by the National Cancer Institute to occur in up to 80%...

PUBLICIS GROUPE DISRUPTS SPORTS MARKETING LANDSCAPE WITH ACQUISITION OF 160OVER90 160over90 will be integrated with Publicis Sports and powered by the Groupe’s technology assets, Epsilon data, and scale in media to create the world’s premier data-driven sport & culture agency. April 2, 2026 – Paris – Publicis Groupe [Euronext Paris FR0000130577, CAC 40] announces it has entered into a definitive agreement to acquire 160over90, the premier global sports and culture-first agency. The move creates the industry’s leading global platform designed to drive measurable business outcomes by connecting brands to fans and audiences through unmatched technology, data, and scale across sport and culture. 160over90, a division of WME Group, is one of the largest global sports marketing and creative agencies that creates meaningful connections with...

Carla Goulart Peron, MD, Chief Medical Officer at Royal PhilipsCarla Goulart Peron, MD, Chief Medical Officer at Royal PhilipsApril 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed to the Board of Directors of the Medical Device Innovation Consortium (MDIC). Founded in 2012, MDIC is a unique public-private partnership that brings stakeholders across the medical device spectrum together with the US Food and Drug Administration (FDA) and other agency partners to help ensure patient access to medical device innovations. “We are delighted to welcome Carla to MDIC’s Board of Directors,” said Andrew C. Fish, President and CEO of MDIC. “She brings deep experience bridging...